Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Tiamenidine
Clinical data | |
---|---|
Trade names | Sundralen, Symcorad, Symcor |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 2.3–5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H10ClN3S |
Molar mass | 215.70 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Tiamenidine (BAN, USAN, INN, also known as thiamenidine, Hoe 440) is an imidazoline compound that shares many of the pharmacological properties of clonidine. It is a centrally-acting α2 adrenergic receptor agonist (IC50 = 9.1 nM). It also acts as an α1-adrenergic receptor agonist to a far lesser extent (IC50 = 4.85 μM). In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output. It was marketed (as tiamenidine hydrochloride) by Sanofi-Aventis under the brand name Sundralen for the management of essential hypertension.
Synthesis
Reaction of thiourea 1 with methyl iodide gives the corresponding S-methyl analogue (2), followed by heating with ethylenediamine, completes the synthesis of tiamenidine (3).
See also
Sympatholytics (antagonize α-adrenergic vasoconstriction) |
|||||
---|---|---|---|---|---|
Other antagonists |
|
||||
|
α1 |
|
||||
---|---|---|---|---|---|
α2 |
|
||||
β |
|
||||